144 related articles for article (PubMed ID: 32732623)
1. PET imaging in testicular tumours.
Calabrò D; Telo S; Ambrosini V
Curr Opin Urol; 2020 Sep; 30(5):665-671. PubMed ID: 32732623
[TBL] [Abstract][Full Text] [Related]
2. Significance of 18F-FDG PET/CT in Characterization of Equivocal Lesions in High-Risk Testicular Carcinoma in Restaging Setting.
Rasheed R; Al-Kandari F; Ghanem M; Marafi F; Usmani S
Asian Pac J Cancer Prev; 2020 Feb; 21(2):511-515. PubMed ID: 32102532
[TBL] [Abstract][Full Text] [Related]
3. The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Loriot Y; Texier M; Culine S; Fléchon A; Thiery-Vuillemin A; Gravis G; Geoffrois L; Chevreau C; Gross-Goupil M; Barthelemy P; Bompas E; Mahammedi H; Laguerre B; Lacourtoisie SA; Helissey C; Ladoire S; Abraham C; Massard C; Grimaldi S; Fizazi K
Eur Urol; 2022 Aug; 82(2):172-179. PubMed ID: 35599187
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDG PET/CT impact on testicular tumours clinical management.
Ambrosini V; Zucchini G; Nicolini S; Berselli A; Nanni C; Allegri V; Martoni A; Rubello D; Cricca A; Fanti S
Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):668-73. PubMed ID: 24265073
[TBL] [Abstract][Full Text] [Related]
5. The role of 18F-FDG PET/CT in the management of testicular cancers.
Cook GJ; Sohaib A; Huddart RA; Dearnaley DP; Horwich A; Chua S
Nucl Med Commun; 2015 Jul; 36(7):702-8. PubMed ID: 25757201
[TBL] [Abstract][Full Text] [Related]
6. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse.
Hain SF; O'Doherty MJ; Timothy AR; Leslie MD; Harper PG; Huddart RA
Br J Cancer; 2000 Oct; 83(7):863-9. PubMed ID: 10970686
[TBL] [Abstract][Full Text] [Related]
7. The role of
Hung TJ; McLean L; Mitchell C; Pascoe C; Lawrentschuk N; Murphy DG; Iravani A; Singh D; Hofman MS; Zidan L; Akhurst T; Lewin J; Hicks RJ
Cancer Imaging; 2019 May; 19(1):28. PubMed ID: 31142361
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors.
Tsatalpas P; Beuthien-Baumann B; Kropp J; Manseck A; Tiepolt C; Hakenberg OW; Burchert W; Franke WG; Wirth MP
Urol Int; 2002; 68(3):157-63. PubMed ID: 11919460
[TBL] [Abstract][Full Text] [Related]
9. Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up.
Conduit C; Koh TT; Hofman MS; Toner GC; Goad J; Lawrentschuk N; Tai KH; Lewin JH; Tran B
Cancer Imaging; 2022 Oct; 22(1):58. PubMed ID: 36209121
[TBL] [Abstract][Full Text] [Related]
10. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours.
Spermon JR; De Geus-Oei LF; Kiemeney LA; Witjes JA; Oyen WJ
BJU Int; 2002 Apr; 89(6):549-56. PubMed ID: 11942962
[TBL] [Abstract][Full Text] [Related]
11. [Positron emission tomography in germ cell tumors in men : Possibilities and limitations].
Schriefer P; Hartmann M; Oechsle K; Meyer CP; Klutmann S; Fisch M; Bokemeyer C; Oing C
Urologe A; 2019 Apr; 58(4):418-423. PubMed ID: 30374517
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma.
Alongi P; Evangelista L; Caobelli F; Spallino M; Gianolli L; Midiri M; Picchio M
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):85-94. PubMed ID: 28828589
[TBL] [Abstract][Full Text] [Related]
13. PET in testicular cancer.
Becherer A
Methods Mol Biol; 2011; 727():225-41. PubMed ID: 21331937
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic accuracy of 18F-FDG-PET in patients with testicular cancer: a meta-analysis.
Zhao JY; Ma XL; Li YY; Zhang BL; Li MM; Ma XL; Liu L
Asian Pac J Cancer Prev; 2014; 15(8):3525-31. PubMed ID: 24870751
[TBL] [Abstract][Full Text] [Related]
15. False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma.
Decoene J; Winter C; Albers P
Urol Oncol; 2015 Jan; 33(1):23.e15-23.e21. PubMed ID: 25454484
[TBL] [Abstract][Full Text] [Related]
16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
17. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals.
Becherer A; De Santis M; Karanikas G; Szabó M; Bokemeyer C; Dohmen BM; Pont J; Dudczak R; Dittrich C; Kletter K
Eur J Radiol; 2005 May; 54(2):284-8. PubMed ID: 15837411
[TBL] [Abstract][Full Text] [Related]
18. Role of
Dolci C; Ceppi L; Guerra L; Crivellaro C; Lamanna M; Adorni M; Elisei F; Bonazzi CM; Sina F; Fruscio R; Messa C
Int J Gynecol Cancer; 2019 Oct; 29(8):1298-1303. PubMed ID: 31366569
[TBL] [Abstract][Full Text] [Related]
19. Re: 18F-FDG PET/CT Impact on Testicular Tumours Clinical Management.
Richie JP
J Urol; 2015 Oct; 194(4):991. PubMed ID: 26382779
[No Abstract] [Full Text] [Related]
20. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
Pfannenberg AC; Oechsle K; Kollmannsberger C; Dohmen BM; Bokemeyer C; Bares R; Vontheim R; Claussen CD
Rofo; 2004 Jan; 176(1):76-84. PubMed ID: 14712410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
